Eli Lilly and Company (NYSE:LLY) Price Target Increased to $1,100.00 by Analysts at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY - Free Report) had its target price hoisted by JPMorgan Chase & Co. from $1,050.00 to $1,100.00 in a research note published on Friday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages also recently weighed in on LLY. Berenberg Bank upped their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a buy rating in a report on Wednesday, August 14th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a buy rating in a research note on Friday, August 16th. Truist Financial restated a buy rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an overweight rating in a research note on Friday, August 9th. Finally, Morgan Stanley restated an overweight rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of Moderate Buy and an average price target of $977.35.

Eli Lilly and Company Trading Down 1.2 %

NYSE:LLY traded down $11.31 on Friday, reaching $923.71. 2,009,766 shares of the company's stock were exchanged, compared to its average volume of 3,042,274. The firm has a market capitalization of $877.92 billion, a price-to-earnings ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business has a fifty day moving average of $896.94 and a 200-day moving average of $831.83.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 646,878 shares of company stock valued at $591,465,138 in the last ninety days. Insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the business. Independent Advisor Alliance raised its position in Eli Lilly and Company by 1.7% in the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company's stock worth $18,810,000 after acquiring an additional 544 shares in the last quarter. Capital Planning LLC purchased a new stake in Eli Lilly and Company during the first quarter worth about $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in Eli Lilly and Company during the first quarter worth about $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company in the first quarter valued at about $8,896,000. Finally, IPG Investment Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $351,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.